NCT00367640View on ClinicalTrials.gov

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

628

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Allergy
Interventions
DRUG

100 IR grass pollen allergen extract tablet

One sublingual tablet daily during 4 months before pollen season and during pollen season

DRUG

300 IR grass pollen allergen extract tablet

One sublingual tablet daily during 4 months before pollen season and during pollen season

DRUG

500 IR grass pollen allergen extract tablet

One sublingual tablet daily during 4 months before pollen season and during pollen season

DRUG

Placebo tablet

One sublingual tablet daily during 4 months before pollen season and during pollen season

Sponsors

Lead Sponsor

Stallergenes Greer
All Listed Sponsors
lead

Stallergenes Greer

INDUSTRY

NCT00367640 - Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter